Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Tamiem Adam"'
Autor:
Udit Nindra, Adel Shahnam, Samuel Stevens, Abhijit Pal, Adnan Nagrial, Jenny Lee, Po Yee Yip, Tamiem Adam, Michael Boyer, Steven Kao, Victoria Bray
Publikováno v:
Thoracic Cancer, Vol 13, Iss 21, Pp 3058-3062 (2022)
Abstract Sustained elevation in neutrophil‐to‐lymphocyte ratio (NLR) after initial chemoradiotherapy (CRT) has been shown to correlate with worse prognosis in a number of solid organ malignancies. Here, we conducted a retrospective observational
Externí odkaz:
https://doaj.org/article/7a4cd723958e4e11906e35ac25e41b11
Autor:
Kate Wilkinson, Sally Jackson, Nicola Jones, Weon Sup Lee, Jin-San Yoo, Eugene Moylan, Tamiem Adam, Jeannette Devoto, Seon Young Lee, Silvie Radmil, Aflah Roohullah, Arlene Chan
Publikováno v:
Cancer Research. 81:PS10-18
Background: Metastatic TNBC (mTNBC) has a poor prognosis. Preclinical data suggests benefit for combination therapy of immune checkpoint inhibitor and anti-angiogenesis. Olinvacimab (O) is a fully humanised monoclonal antibody (MAB) which binds to Va
Autor:
Udit Nindra, Samuel Xavier Stevens, Adel Shahnam, Abhijit Pal, Tamiem Adam, Po Yee Yip, Jenny HJ Lee, Michael J. Boyer, Adnan Nagrial, Steven Chuan-Hao Kao, Victoria Jane Bray
Publikováno v:
Journal of Clinical Oncology. 40:e18810-e18810
e18810 Background: The PACIFIC trial established concurrent chemoradiation followed by one year of consolidation durvalumab as the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, the data to support the use of
Autor:
Udit Nindra, Adel Shahnam, Samuel Xavier Stevens, Abhijit Pal, Po Yee Yip, Tamiem Adam, Jenny HJ Lee, Michael J. Boyer, Adnan Nagrial, Steven Chuan-Hao Kao, Victoria Jane Bray
Publikováno v:
Journal of Clinical Oncology. 40:e18773-e18773
e18773 Background: The neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has been of prognostic interest in lung cancer. Sustained NLR and PLR after initial chemoradiotherapy (CRT) has been shown to correlate with worse prog
Autor:
Samuel Xavier Stevens, Udit Nindra, Adel Shahnam, Victoria Jane Bray, Po Yee Yip, Tamiem Adam, Jenny HJ Lee, Michael J. Boyer, Adnan Nagrial, Steven Chuan-Hao Kao
Publikováno v:
Journal of Clinical Oncology. 40:e18809-e18809
e18809 Background: Consolidation treatment with durvalumab following CRT is now standard of care for pts with unresectable stage III NSCLC. In PACIFIC, durvalumab was administered within 42 days of completing CRT. There has also been recent interest
Publikováno v:
Cancers, Vol 13, Iss 277, p 277 (2021)
Cancers
Cancers
Simple Summary There have been significant advances in the treatment of cancer within the past 10 years. Immunotherapy is a new type of treatment which uses the body’s own immune system to fight cancer. In some cancers, including lung, melanoma, bl
Autor:
Nindra, Udit1 (AUTHOR) udit.nindra@health.nsw.gov.au, Shahnam, Adel2 (AUTHOR), Stevens, Samuel3 (AUTHOR), Pal, Abhijit1 (AUTHOR), Nagrial, Adnan2,4 (AUTHOR), Lee, Jenny3,5 (AUTHOR), Yip, Po Yee6,7 (AUTHOR), Adam, Tamiem8 (AUTHOR), Boyer, Michael3,4 (AUTHOR), Kao, Steven3,4 (AUTHOR), Bray, Victoria1,8 (AUTHOR)
Publikováno v:
Thoracic Cancer. Nov2022, Vol. 13 Issue 21, p3058-3062. 5p.
Publikováno v:
Asia Pacific Journal of Clinical Oncology. Nov2018 Supplement S7, Vol. 14, p25-49. 25p.
Autor:
Adam, Tamiem1,2,3 (AUTHOR) Victoria.bray@health.nsw.gov.au, Becker, Therese M.1,4 (AUTHOR) wei.chua@health.nsw.gov.au, Chua, Wei1,2,3 (AUTHOR), Bray, Victoria3 (AUTHOR), Roberts, Tara L.1,2,4 (AUTHOR) tamiem_adam@live.com
Publikováno v:
Cancers. Jan2021, Vol. 13 Issue 2, p277-277. 1p.